Amyloid deposition occurs in at least twenty five different human diseases. This project is focused on amyloid formation by Islet Amyloid Polypeptide (IAPP, Amylin), the hormone responsible for pancreatic islet amyloid in type 2 diabetes. IAPP is normally secreted as a soluble polypeptide together with insulin, but aggregates via an unknown mechanism in type 2 diabetes to form extracellular islet amyloid. Islet amyloid, or the process of its formation, is toxic to ?-cells and contributes to the patholog of type 2 diabetes. Amyloid formation by IAPP has been recently shown to be a major complicating factor in islet cell transplantation. Diabetes has reached epidemic proportions in the United States and is emerging as a major health threat in the developing world. Relatively little is known about the mechanism of amyloid formation by IAPP or about the nature of the toxic species generated during its formation. The research will (I) determine the mechanism of amyloid formation by IAPP;(II) examine the effects of a mutation in IAPP which has been proposed to be linked to early onset diabetes;(III) define the most toxic species populated during amyloid assembly and define their conformational properties;(IV) critically test the hypotheses that accelerating amyloid formation reduces IAPP induced cytotoxicity. The research will provide insight into strategies for the treatment of type 2 diabetes and for the prevention of islet graft failure after transplantation. The lessons learned will also aid in the design of more soluble variants of IAPP to treat type 1 diabetes. An interdisciplinary combination of experimental biophysics, biochemistry and cell biology will be used to address these issues. The methods being developed are expected to be broadly applicable and will aid efforts to better control amyloid formation in other diseases.
Five specific aims will be carried out. The first involves studies of the mechanism of amyloid formation by IAPP.
The second aim will examine the basis for enhanced amyloid formation by a natural mutant of human IAPP.
The third aim will interrogate the conformational properties of toxic intermediates populated during amyloid formation by IAPP using high resolution methods, while the fourth aim will conduct comparative studies of toxic and non-toxic IAPP inhibitor complexes.
The final aim will test a new strategy for preventing IAPP toxicity.

Public Health Relevance

The pancreatic hormone IAPP aggregates in type 2 diabetes to form pathological deposits known as amyloid which kill the insulin producing beta-cells. IAPP amyloid deposits are also believed to be a major complicating factor in islet cell transplantation. This project will determine the mechanism of amyloid formation by IAPP and will develop methods for preventing it. Diabetes is reaching epidemic proportions in the Western World and this project will have a direct impact on human health.

National Institute of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
Research Project (R01)
Project #
Application #
Study Section
Macromolecular Structure and Function B Study Section (MSFB)
Program Officer
Wehrle, Janna P
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
State University New York Stony Brook
Schools of Arts and Sciences
Stony Brook
United States
Zip Code
Wang, Hui; Abedini, Andisheh; Ruzsicska, Bela et al. (2014) Rationally designed, nontoxic, nonamyloidogenic analogues of human islet amyloid polypeptide with improved solubility. Biochemistry 53:5876-84
Tu, Ling-Hsien; Noor, Harris; Cao, Ping et al. (2014) Aspirin, diabetes, and amyloid: re-examination of the inhibition of amyloid formation by aspirin and ketoprofen. ACS Chem Biol 9:1632-7
Wang, Hui; Raleigh, Daniel P (2014) The ability of insulin to inhibit the formation of amyloid by pro-islet amyloid polypeptide processing intermediates is significantly reduced in the presence of sulfated glycosaminoglycans. Biochemistry 53:2605-14
Young, Lydia M; Cao, Ping; Raleigh, Daniel P et al. (2014) Ion mobility spectrometry-mass spectrometry defines the oligomeric intermediates in amylin amyloid formation and the mode of action of inhibitors. J Am Chem Soc 136:660-70
Susa, Anna C; Wu, Chun; Bernstein, Summer L et al. (2014) Defining the molecular basis of amyloid inhibitors: human islet amyloid polypeptide-insulin interactions. J Am Chem Soc 136:12912-9
Wang, Hui; Raleigh, Daniel P (2014) General amyloid inhibitors? A critical examination of the inhibition of IAPP amyloid formation by inositol stereoisomers. PLoS One 9:e104023
Tu, Ling-Hsien; Serrano, Arnaldo L; Zanni, Martin T et al. (2014) Mutational analysis of preamyloid intermediates: the role of his-tyr interactions in islet amyloid formation. Biophys J 106:1520-7
Wang, Hui; Cao, Ping; Raleigh, Daniel P (2013) Amyloid formation in heterogeneous environments: islet amyloid polypeptide glycosaminoglycan interactions. J Mol Biol 425:492-505
Tu, Ling-Hsien; Raleigh, Daniel P (2013) Role of aromatic interactions in amyloid formation by islet amyloid polypeptide. Biochemistry 52:333-42
Cao, Ping; Abedini, Andisheh; Raleigh, Daniel P (2013) Aggregation of islet amyloid polypeptide: from physical chemistry to cell biology. Curr Opin Struct Biol 23:82-9

Showing the most recent 10 out of 36 publications